An Implantable Sensor ‘LAP-Sense’ for Remote/Continuous Monitoring of Complex Cardiovascular Patients

每年，心血管疾病(CVD)导致的死亡占全球死亡总数的24%，即每年1800万人，其中85%的死亡是由中风、心力衰竭(HF)和房颤(AF)造成的。英国有600多万CVD患者，每年花费74亿GB的医疗费用和158亿GB的经济损失。传统上，临床医生专注于生理指标(患者体重/血压等)来检测恶化的CVD。不幸的是，这些标记物在失代偿的时间进程中出现得较晚。许多研究表明房颤是心衰病理生理学的驱动因素，反之亦然。根据弗雷明翰心脏研究，57%的心衰患者会发生房颤。这导致住院、中风和死亡的风险大大增加。因此，这为拥有同时治疗心力衰竭和房颤最大风险(即中风)的单一设备提供了强有力的证据。目前治疗这些患有房颤和心力衰竭的复杂患者的方法需要多个昂贵的设备和高风险的程序。通过这个项目，RECO和他们的合作伙伴Aurigen正在开发世界上第一个可植入的心脏监测传感器‘LAP-SENSE’，用于远程/连续监测CVD患者，该传感器与左房附件闭塞(LAAO)设备完全集成。这个为期18个月的工业研究项目利用了RECO的传感器技术，该技术将与Aurigen的Zenith设备集成，用于LAP监测和LAAO。RECO和Aurigen正在根据心脏病专家的反馈和要求开发一种产品，以协同满足数百万房颤和心力衰竭患者的需求。这将在LAAO的中风预防能力的基础上提供改进的诊断能力，在同一程序中植入单个设备，将当前的护理标准提升到新的安全、效率和成本效益水平。

Every year, Cardiovascular Disease (CVD) causes 24% of all deaths worldwide or 18million/annum, with 85% of fatalities due to stroke, heart failure (HF) and atrial fibrillation (AF). The UK has over 6 million CVD sufferers, costing £7.4billion/annum in healthcare costs and £15.8billion/annum in economic losses.Traditionally, clinicians have focused on physiological markers (patient-weight/blood-pressure etc) to detect worsening CVD. Unfortunately, these markers appear late in the time course of decompensation. Relying on them leaves little time to respond before hospitalization is necessary.Many studies have shown that AF drives HF pathophysiology and vice versa. According to the Framingham Heart Study, AF occurred in 57% of the individuals with HF. This leads to huge increased risk of hospitalization, stroke and death. Therefore, this presents a strong case to have a single device that simultaneously treats both HF and the greatest risk of AF, namely stroke. Current approaches to treat these complex patients, suffering from AF & HF, requires multiple expensive devices and risky procedures.Through this project, RECO and their collaborator AuriGen are developing world's first implantable cardiac monitoring sensor 'LAP-Sense' for remote/continuous monitoring of CVD patients, which is fully integrated with a Left Atrial Appendage Occlusion (LAAO) device. This 18-month industrial research project utilizes RECO's sensor technology, which will be integrated with AuriGen's Zenith device to be used for LAP monitoring and LAAO.RECO & AuriGen, based on feedback and requests from cardiologists, are developing a product to synergistically address needs of millions AF & HF sufferers. This will offer improved diagnostics in addition to the stroke prevention capabilities of an LAAO, in a single device, implanted in the same procedure, elevating the current standard of care to new levels of safety, efficacy and cost effectiveness.